5-[2-(oxan-4-yl)ethyl]-3-pyrimidin-5-yl-7,8-dihydro-6H-pyrazino[2,3-b]pyrazine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-[2-(oxan-4-yl)ethyl]-3-pyrimidin-5-yl-7,8-dihydro-6H-pyrazino[2,3-b]pyrazine
• 化学式: C₁₇H₂₂N₆O
• 分子量: 326.4
• InChiKey: SZRLCAFYJMIZBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
  申请人：Signal Pharmaceuticals, LLC

  公开号：US10004735B2

  公开（公告）日：2018-06-26

  Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer.

  本文提供了治疗或预防癌症的方法，包括向癌症患者施用有效量的 TOR 激酶抑制剂和有效量的第二种活性剂。
• Treatment of cancer with TOR kinase inhibitors
  申请人：Signal Pharmaceuticals, LLC

  公开号：US11166950B2

  公开（公告）日：2021-11-09

  Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.

  本文提供了治疗或预防患者实体瘤、非霍奇金淋巴瘤或多发性骨髓瘤的方法，包括向患有实体瘤、非霍奇金淋巴瘤或多发性骨髓瘤的患者施用有效量的TOR激酶抑制剂。
• INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY
  申请人：SIGNAL PHARMACEUTICALS, LLC

  公开号：US20140113905A1

  公开（公告）日：2014-04-24

  Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3β or p70S6K1, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3β or p70S6K1.
• METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY
  申请人：SIGNAL PHARMACEUTICALS, LLC

  公开号：US20140314751A1

  公开（公告）日：2014-10-23

  Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide to a patient having a cancer.
• TREATMENT OF CANCER CHARACTERIZED BY GENE MUTATIONS
  申请人：SIGNAL PHARMACEUTICALS, LLC

  公开号：US20150099754A1

  公开（公告）日：2015-04-09

  Provided herein are methods for treating and/or preventing a cancer in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer characterized by particular gene mutation(s) or variant(s) relative to the genes of a biological wild-type sample.